Oak Thistle LLC’s ResMed RMD Stock Holding History

Oak Thistle LLC’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,930	Closed	-$332K	–	478
2023 Q4	$332K	Buy	+1,930	New	+$297K	0.1%	344
2023 Q3	–	Sell	-2,893	Closed	-$632K	–	583
2023 Q2	$632K	Sell	2,893 -2,590	-47%	-$577K	0.33%	119
2023 Q1	$1.2M	Buy	5,483 +3,982	+265%	+$864K	0.71%	5
2022 Q4	$312K	Buy	+1,501	New	+$330K	0.67%	57
2022 Q2	–	Sell	-5,369	Closed	-$1.3M	–	373
2022 Q1	$1.3M	Buy	5,369 +3,895	+264%	+$942K	0.69%	6
2021 Q4	$384K	Buy	+1,474	New	+$382K	0.3%	152

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oak Thistle LLC's RMD Position: Q1 2024 in Review

Oak Thistle LLC sold out of ResMed (RMD) in Q1 2024, closing a stake of 1,930 shares — an estimated $332K sold.

Oak Thistle LLC first reported a position in RMD in Q4 2021 and held it in 6 quarters. The position peaked at $1.3M in Q1 2022. 718 funds tracked by Wall St. Rank hold RMD as of Q1 2024.

Oak Thistle LLC reported no remaining ResMed position as of Q1 2024 after selling out during the quarter.
Oak Thistle LLC sold 1,930 ResMed shares in Q1 2024, an estimated $332K.
Oak Thistle LLC first reported a position in ResMed in Q4 2021 and held it in 6 quarters.
Oak Thistle LLC's ResMed position peaked at $1.3M in Q1 2022.
718 funds tracked by Wall St. Rank held ResMed as of Q1 2024.

Based on Oak Thistle LLC's 13F filing for Q1 2024, filed 18 Apr 2024.